Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Alpine Immune Sciences Inc (NQ: ALPN)
3.700 USD  +0.080 (+2.21%)
Official Closing Price  /  Updated: 4:00 PM EDT, May 29, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 18,700
Open 3.750
Bid (Size) 3.180 (3)
Ask (Size) 3.800 (3)
Prev. Close 3.620
Today's Range 3.600 - 3.940
52wk Range 2.050 - 5.350
Shares Outstanding 13,849,562
Dividend Yield N/A
Performance
YTD
+2.12%
+2.12%
1 Month
+23.33%
+23.33%
3 Month
+18.59%
+18.59%
6 Month
+22.11%
+22.11%
1 Year
-25.85%
-25.85%
Top News
More News
Alpine Immune Sciences Announces Poster Presentations at EULAR 2020
Alpine Immune Sciences Announces Poster Presentations at EULAR 2020 Read More
from Business Wire News Releases
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference
Alpine Immune Sciences to Participate in Fireside Chat at the Jefferies Virtual Global Healthcare Conference Read More
from Business Wire News Releases
More News
Read More
Alpine Immune Sciences Reports First Quarter 2020 Financial Results and Provides Company Update
from Business Wire News Releases
Alpine Immune Sciences Presents Design of the ALPN-202 Phase 1 Study (NEON-1) at AACR Virtual Annual Meeting I
from Business Wire News Releases
Alpine Immune Sciences Announces Poster Presentation at AACR Virtual Annual Meeting I
from Business Wire News Releases
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
from Business Wire News Releases
Alpine Immune Sciences’ ALPN-101 Receives FDA Orphan Drug Designations for the Prevention and Treatment of Acute Graft Versus Host Disease
from Business Wire News Releases
Alpine Immune Sciences Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference
from Business Wire News Releases
Alpine Immune Sciences to Present at Two Upcoming Healthcare Investor Conferences
from Business Wire News Releases
Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress ALPN-101 demonstrates efficacy in treatment of chronic inflammatory bowel disease in both in vivo and in vitro
from Business Wire News Releases
Alpine Immune Sciences Announces Poster Presentation at 2020 Crohn’s & Colitis Congress
from Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.